FibroGen (FGEN) Misses Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
FibroGen Reports Third Quarter 2018 Financial Results
November 8, 2018 4:02 PM ESTRoxadustat New Drug Applications under Review in China and JapanPhase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time
SAN FRANCISCO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, Â today reported financial results for the third quarter of 2018 and provided an update on the companys recent developments.
With new drug applications for roxadustat in anemia associated... More
